443 related articles for article (PubMed ID: 2416438)
1. 1,25-Dihydroxyvitamin D3: in vivo and in vitro effects on human preleukemic and leukemic cells.
Koeffler HP; Hirji K; Itri L
Cancer Treat Rep; 1985 Dec; 69(12):1399-407. PubMed ID: 2416438
[TBL] [Abstract][Full Text] [Related]
2. Induction of macrophage differentiation of human normal and leukemic myeloid stem cells by 1,25-dihydroxyvitamin D3 and its fluorinated analogues.
Koeffler HP; Amatruda T; Ikekawa N; Kobayashi Y; DeLuca HF
Cancer Res; 1984 Dec; 44(12 Pt 1):5624-8. PubMed ID: 6594194
[TBL] [Abstract][Full Text] [Related]
3. [Treatment of myelodysplastic syndrome and acute myelogenous leukemia with vitamin D3 [1 alpha(OH)D3]].
Irino S; Taoka T
Gan To Kagaku Ryoho; 1988 Apr; 15(4 Pt 2-2):1183-90. PubMed ID: 2837981
[TBL] [Abstract][Full Text] [Related]
4. Alternative differentiation of human promyelocytic leukemia cells (HL-60) induced selectively by retinoic acid and 1 alpha,25-dihydroxyvitamin D3.
Miyaura C; Abe E; Suda T; Kuroki T
Cancer Res; 1985 Sep; 45(9):4244-8. PubMed ID: 2992776
[TBL] [Abstract][Full Text] [Related]
5. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
6. Effect of 1,25-dihydroxyvitamin D3 and 13-cis-retinoic acid on in vitro hematopoiesis in the myelodysplastic syndromes.
Nagler A; Rikilis I; Tatarsky I; Fabian I
J Lab Clin Med; 1987 Aug; 110(2):237-44. PubMed ID: 3474327
[TBL] [Abstract][Full Text] [Related]
7. 19-nor-26,27-bishomo-vitamin D3 analogs: a unique class of potent inhibitors of proliferation of prostate, breast, and hematopoietic cancer cells.
Kubota T; Koshizuka K; Koike M; Uskokovic M; Miyoshi I; Koeffler HP
Cancer Res; 1998 Aug; 58(15):3370-5. PubMed ID: 9699668
[TBL] [Abstract][Full Text] [Related]
8. Combination of a potent 20-epi-vitamin D3 analogue (KH 1060) with 9-cis-retinoic acid irreversibly inhibits clonal growth, decreases bcl-2 expression, and induces apoptosis in HL-60 leukemic cells.
Elstner E; Linker-Israeli M; Umiel T; Le J; Grillier I; Said J; Shintaku IP; Krajewski S; Reed JC; Binderup L; Koeffler HP
Cancer Res; 1996 Aug; 56(15):3570-6. PubMed ID: 8758928
[TBL] [Abstract][Full Text] [Related]
9. 20-Cyclopropyl-cholecalciferol vitamin D3 analogs: a unique class of potent inhibitors of proliferation of human prostate, breast and myeloid leukemia cell lines.
Koike M; Koshizuka K; Kawabata H; Yang R; Taub HE; Said J; Uskokovic M; Tsuruoka N; Koeffler HP
Anticancer Res; 1999; 19(3A):1689-97. PubMed ID: 10470102
[TBL] [Abstract][Full Text] [Related]
10. Biological activities of 26,26,26,27,27,27-hexafluoro-1,25-dihydroxyvitamin D3 on human promyelocytic leukemic HL-60 cells: effects of fetal bovine serum and of incubation time.
Okuno S; Inaba M; Nishizawa Y; Morii H
Miner Electrolyte Metab; 1995; 21(1-3):211-6. PubMed ID: 7565452
[TBL] [Abstract][Full Text] [Related]
11. 1,25(OH)2-16ene-vitamin D3 is a potent antileukemic agent with low potential to cause hypercalcemia.
Jung SJ; Lee YY; Pakkala S; de Vos S; Elstner E; Norman AW; Green J; Uskokovic M; Koeffler HP
Leuk Res; 1994 Jun; 18(6):453-63. PubMed ID: 8207963
[TBL] [Abstract][Full Text] [Related]
12. 1,25-Dihydroxyvitamin D3 and the regulation of the differentiation and function of macrophages and granulocytes.
Shezen E; Goldman R
Int J Cell Cloning; 1985 Mar; 3(2):65-80. PubMed ID: 3839007
[TBL] [Abstract][Full Text] [Related]
13. The novel analog 1,24(S)-dihydroxyvitamin D2 is as equipotent as 1,25-dihydroxyvitamin D3 in growth regulation of cancer cell lines.
Levy Y; Knutson JC; Bishop C; Shany S
Anticancer Res; 1998; 18(3A):1769-75. PubMed ID: 9673403
[TBL] [Abstract][Full Text] [Related]
14. Physician Education: Myelodysplastic Syndrome.
Yoshida Y
Oncologist; 1996; 1(4):284-287. PubMed ID: 10388004
[TBL] [Abstract][Full Text] [Related]
15. Combined differentiation therapy in myelodysplastic syndrome with retinoid acid, 1 alpha,25 dihydroxyvitamin D3, and prednisone.
Blazsek I; Musset M; Boulé D; Labat ML; Bringuier MF; Comisso M; Le Maignan C; Ribaud P; Mathé G; Misset JL
Cancer Detect Prev; 1992; 16(4):259-64. PubMed ID: 1458517
[TBL] [Abstract][Full Text] [Related]
16. Novel vitamin D analogs that modulate leukemic cell growth and differentiation with little effect on either intestinal calcium absorption or bone mobilization.
Zhou JY; Norman AW; Lübbert M; Collins ED; Uskokovic MR; Koeffler HP
Blood; 1989 Jul; 74(1):82-93. PubMed ID: 2665845
[TBL] [Abstract][Full Text] [Related]
17. 24-Oxo metabolites of vitamin D3 analogues: disassociation of their prominent antileukemic effects from their lack of calcium modulation.
Shiohara M; Uskokovic M; Hisatake J; Hisatake Y; Koike K; Komiyama A; Koeffler HP
Cancer Res; 2001 Apr; 61(8):3361-8. PubMed ID: 11309293
[TBL] [Abstract][Full Text] [Related]
18. 5,6-trans-16-ene-vitamin D3: a new class of potent inhibitors of proliferation of prostate, breast, and myeloid leukemic cells.
Hisatake J; Kubota T; Hisatake Y; Uskokovic M; Tomoyasu S; Koeffler HP
Cancer Res; 1999 Aug; 59(16):4023-9. PubMed ID: 10463602
[TBL] [Abstract][Full Text] [Related]
19. Metabolism of vitamin D in human promyelocytic leukemia cells (HL-60) II. Does the differentiation of the cells alter the metabolism?
Imae Y; Shimizu M; Miyaura C; Suda T; Yamada S
Tokyo Ika Shika Daigaku Iyo Kizai Kenkyusho Hokoku; 1989; 23():73-80. PubMed ID: 2488967
[TBL] [Abstract][Full Text] [Related]
20. Antileukemic effect of a synthetic vitamin D3 analog, HY-11, with low potential to cause hypercalcemia.
Yoon JS; Kim JY; Park HK; Kim ES; Ahn KS; Yoon SS; Cho CG; Kim BK; Lee YY
Int J Oncol; 2008 Feb; 32(2):387-96. PubMed ID: 18202761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
